• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Mol Cancer Ther. Author manuscript; available in PMC Apr 1, 2010.
Published in final edited form as:
PMCID: PMC2676893
NIHMSID: NIHMS108030

Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo

Abstract

INTRODUCTION

Histone deacetylase inhibitors (HDACIs) such as valproic acid (VPA) are promising anti-cancer agents that change the acetylation status of histones and loosen the chromatin structure. We assessed nuclear structure changes induced by VPA in prostate cancer (PCa) LNCaP, CWR22R, DU145 and PC3 cell lines and xenografts and their potential use as a biomarker of treatment.

METHODS

In vitro tissue microarrays (TMAs) consisted of PCa cell lines treated for 3, 7 or 14 days with 0, 0.6 or 1.2 mM VPA. In vivo TMAs consisted of cores from PCa xenografts from nude mice treated for 30 days with 0.2% or 0.4% VPA in drinking water. Digital images of at least 200 Feulgen-DNA stained nuclei were captured using the Nikon CoolScope and nuclear alterations were measured.

RESULTS

With a set of seven most frequently significant nuclear alterations (determined by univariate logistic regression analysis) control and VPA treatment nuclei were compared in vitro and in vivo. Depending on the cell line, AUC-ROCs ranged between 0.6−0.9 and were dose- and time-dependent both in vitro and in vivo. Also, VPA treatment caused significant nuclear alterations in normal drug filtering organs i.e. liver and kidney tissue.

CONCLUSION

In vitro and in vivo VPA treatment of PCa cell lines results in significant dose- and time dependent changes in nuclear structure. Further, VPA induces nuclear structural changes in normal liver and kidney tissue, which likely reflects a natural physiological response. Therefore, nuclear structural alterations may serve as a biomarker for HDACI treatment.

INTRODUCTION

Acetylation of histones and other nuclear proteins plays an important role in cancer development and progression (1). Deregulation of the balance between Histone Acetyl Transferases (HAT) and Histone Deacetylase (HDACs) has been associated with oncogenesis in many tissues (2, 3). Histone deacetylase inhibitors (HDACIs) are promising anti-cancer agents that have shown stable disease and partial responses in a wide range of solid malignancies, including prostate cancer (PCa) (4, 5). Recently, the FDA approved HDACI vorinostat for the treatment of advanced cutaneous T-cell lymphoma. Clinical trials treating solid tumors with HDACI valproic acid (VPA) alone or combination are ongoing (6-8). Recently, two phase I clinical trials were published using VPA in combination with methyltransferase inhibitor 5-azacytidine or topoisomerase II inhibitor epirubicin (9, 10). These trials showed pharmacokinetic properties and toxicity profiles of VPA in patients with solid malignancies. In addition, stable disease and partial responses were reported in up to 39% and 22% of patients respectively.

HDACIs change the acetylation status of histones thereby enhancing the accessibility of the transcription and DNA repair machinery to DNA (11, 12). In addition to changing DNA accessibility by histone acetylation, HDACIs affect transcription, acetylation status and function of proteins that are important for DNA mobility, DNA structure and regulation of DNA accessibility (1, 13). Among these proteins are high mobility group (HMG) proteins (14-17), nuclear matrix proteins (18), tubulin (19, 20) and members of SWI/SNF complex (21).

Diamond and associates (22) were the first to employ nuclear structure measurements (nuclear roundness factor) by digital imaging to predict PCa outcome. Subsequently, several investigators (23-28) have used nuclear alterations to predict pathologic stage and prognosis for PCa patients. Nuclear morphometric alterations measured by computer-assisted image analysis can detect abnormal DNA content representing large scale chromosomal alterations (i.e. tetraploidy, aneuploidy) reflecting genetic instability in tumor cells (29, 30). In addition, alterations in nuclear size, shape, and texture can be measured. In the current study we assessed the nuclear structure changes induced by VPA treatment in PCa cell lines and xenografts and their potential use as a biomarker of treatment.

MATERIALS AND METHODS

Tissue Microarray (TMA)

In Vitro

The LNCaP, PC3, DU145 and C4−2 cell lines were grown in RPMI 1640 with L-glutamine (Cellgro, Herndon, VA, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Life Technologies, Inc., Carlsbad, CA, USA), 5 μg/mL ciprofloxacin hydrochloride (U.S. Biological, Swampscott, MA, USA), and 50 μg/mL gentamicin (Quality Biological, Inc., Gaithersburg, MD, USA). Cells were allowed to grow until 80% to 90% confluent and harvested with 0.05% trypsin/0.53 mmol/L EDTA (Cellgro) before each subsequent passage. VPA (1 mol/L; VPA sodium salt; Sigma, St. Louis, MO, USA) stock was made in PBS and filters sterilized through a 0.22-μm filter. The in vitro TMA consisted of core cell plugs from formalin-fixed paraffin embedded (FFPE) human PCa cell lines LNCaP, C4−2, DU145 and PC3. Cells were treated for 3, 7 or 14 days with 0, 0.6 or 1.2 mM VPA and resuspended in agarose prior to harvesting and paraffin embedding.

In Vivo

Human PCa cell lines LNCaP, PC3, DU145 and C4−2 were allowed to grow to 80% to 90% confluency and harvested as described above. Cells were resuspended in 1× phosphate-buffered saline (pH 7.4; BioSource, Rockville, MD, USA), mixed 1× with Matrigel (BD Biosciences, Palo Alto, CA, USA), and injected (1 × 106 per injection) subcutaneously into the lateral flanks of male athymic nu/nu mice. Once palpable tumors were established, animals were randomized into control and treatment arms with the latter receiving 0.2% or 0.4% VPA in drinking water for 30 days prior to formalin fixation and paraffin embedding.

TMAs were prepared using a Beecher MT1 manual arrayer (Beecher Instruments, Silver Spring, MD, USA). From FFPE tissue blocks a spot was punched and transferred to a recipient block. The in vitro TMA was constructed using two or three serial 0.60 mm core tissue samples from each cell plug. The in vivo TMA was constructed using two serial 0.60 mm core tissue samples from each of the 4−10 replicate xenografts and six micron slides were prepared from each TMA.

Digital Measurement of Nuclear Morphometric Alterations

Feulgen DNA-staining was performed per manufacturer's instructions (TriPath Imaging Inc, Burlington, NC, USA). Feulgen specifically and quantitatively stains DNA in cellular material by uncovering the free aldehyde groups in the DNA during the acid hydrolysis process, which then reacts with the Feulgen reagent to form a stable, blue color that absorbs light at 560 nm (31, 32). Figure 1 shows Feulgen-stained in vitro and in vivo TMA spots.

Figure 1
Feulgen stained nuclei from PCa cell line PC3. Untreated PCa cells are smaller in diameter and more intensely stained than cells that have been either treated in vitro for 14 days with 1.2 mM VPA (panel A) or in vivo for 30 days with 0.4% VPA in drinking ...

Next, a minimum of 200 nuclei was captured from each TMA spot using Nikon CoolScope imaging system with pathology software suite designed by Bacus Laboratories (Lombard, IL, USA). The software calculates a total of 39 nuclear structure alterations using a single-step pixel analysis of each nucleus to quantitatively characterize nuclear size, shape, DNA content, and chromatin texture features. Tables 1 & 2 shows the number of nuclei captured from each treatment arm.

Table 1
Summary of in vitro samples used to study the effect of the HDACI valproic acid on nuclear morphometry of prostate cancer cell lines.
Table 2
Summary of in vivo samples used to study the effect of the HDACI valproic acid on nuclear morphometry of prostate cancer cell lines and normal tissue.

Statistical Analysis

All data was analyzed using Stata™ v10.0 statistical analysis software (Stata Corporation, College Station, TX, USA). Univariate logistic regression analysis was performed to determine which independent variables significantly differentiate between VPA vs. control groups. Two sets of the most common univariately significant nuclear structure alterations, one for in vitro and one for in vivo experiments, were chosen to compare VPA response using area under the receiver operator characteristic (AUC-ROC) curves across different doses and different durations for in vitro and in vivo experiments. Statistical significance in this study was set as p ≤ 0.05.

RESULTS

VPA causes dose- and time-dependent changes in PCa nuclei in vitro

To assess nuclear structure changes induced by VPA treatment in LNCaP, C4−2, DU145 and PC3 cell lines; 39 features of nuclear size and shape, texture, and DNA content were measured using Nikon CoolScope imaging system (supplementary text contains definition of all features). Univariate logistic regression analysis with a variable selection stringency of Pz ≤ 0.05 was performed to identify significant alterations in nuclear structure after treatment with VPA for each cell line at each given dose and duration of treatment (supplementary table 1). A set of the 7 most frequently significant nuclear structural alterations was selected in order to compare VPA drug response across all PCa cell lines tested at each given dose and duration of treatment. These included maximum diameter, peak, valley, difference entropy, information measure A, maximum correlation and product moment. Figure 2 demonstrates that alterations in nuclear structure were dose- and time dependent and highest at 14 days of treatment with 1.2 mM VPA. The increase in VPA response was minimal when 3 days treatment was compared to 7 days treatment. The PC3 nuclei showed the largest change in nuclear structure compared to LNCaP, C4−2 and DU-145 at 14 days of treatment with 1.2 mM VPA. We were unable to capture sufficient nuclear images at Day 3 and Day 7 for PC3 cell line with 0.6 mM VPA and 1.2 mM VPA, and Day 7 with 0.6 mM VPA for DU-145 cell line. These were therefore excluded from analysis.

Figure 2
Summary of AUC-ROC statistics of control versus in vitro treated cell lines. A, B, C and D respectively show response (AUC-ROCs) of C4−2, LNCaP, DU-145 and PC3 cell lines treated in vitro at different doses (0, 0.6 mM, and 1.2 mM VPA) and durations ...

In vivo treatment with VPA results in nuclear structure changes

To determine whether the changes seen in vitro also occur in vivo, LNCaP, CWR22R, DU145 and PC3 xenografts were analyzed. Univariate logistic regression analysis with a variable selection stringency level of Pz ≤ 0.05 was performed to identify significant alterations in nuclear structure in xenografts after treatment of nude mice with VPA (supplementary table 2). A set of the 7 most frequently significant nuclear structural alterations were selected to compare VPA response across all xenograft experiments. These included. maximum diameter, minimum diameter, average OD, standard deviation, peak, valley and triangular symmetry. Figure 3 shows that the quantitative changes in nuclear structure seen in vivo are dose-dependent. The extent of structural changes differed across different xenografts. The C4−2 xenograft tumors treated with 0.4% VPA treatment for 30 days showed the most pronounced change of all tested xenografts.

Figure 3
Summary of AUC-ROC statistics of control versus in vivo treated cell lines showing response (AUC-ROCs) of DU145, LNCaP, CWR22R, PC3 and C4−2 cell lines treated in vivo with different doses (0, 0.2% and 0.4%) VPA in drinking water for 30 days ( ...

VPA treatment causes nuclear structural changes in normal liver and kidney

To assess whether VPA treatment also affects nuclear structure in drug metabolizing and filtering organs that appear normal by H&E staining, we captured images of normal liver and kidney cell nuclei 30 days after injection of tumor cells and compared them with mice injected and treated for 30 days with 0.4% VPA. Supplementary table 2 shows significant nuclear alterations in liver and kidney after treatment. Using the above mentioned xenograft set of significant nuclear structure alterations i.e. maximum diameter, minimum diameter, average OD, standard deviation, peak, valley and triangular symmetry, AUC-ROCs for liver and kidney were 0.64 and 0.71 respectively.

DISCUSSION

Malignant diseases are exemplified by aberrant transcriptional regulation which may be triggered by a change in recruitment of HDACs to the site of transcriptional initiation (33). Screening of HDAC expression in human PCa has revealed distinct class I HDAC profiles between stromal and epithelial cells (34) and in vitro experiments with PCa cell lines has shown a marked increase in HDAC levels for most HDACs compared to normal prostate tissue (35). Although it is thought that acetylation of histones is required for gene expression, inhibiting HDACs does not result in whole genome re-expression. In fact, about half of the genes that are differentially expressed after VPA treatment are down-regulated (36).

Nuclear organization and chromatin dynamics have regained interest since recent reports suggest that in interphase cells, gene activation and replication is associated with repositioning of the genetic locus relative to the nuclear compartment and other genomic loci (37, 38). Although individual chromosomes occupy distinct positions in the nucleus called chromosome territories (39), locus-specific movement within and across these boundaries occurs throughout the interphase. The (extent of) mobility of individual loci depends on nuclear localization (40), phase in cell cycle (41), location on the chromosome (42) and might be actin-, myosin and ATP-dependent (43, 44). Although in many cases repositioning of activated genes is oriented towards the nuclear interior (44-48), there is not always a strict correlation between movement away from the periphery and gene activation (46, 47, 49). The purpose of these movements and the means by which this is possible is under intense debate. It is suggested that chromatin mobility may facilitate access for enzymes involved in histone modifications, nucleosome remodeling and the ensuing folding or unfolding of the domain (38). Recently investigators have described the existence of regulatory cross-talk between ‘kissing’ loci within and across chromosomes suggesting the existence of spatial networks of gene regulation. They propose that interacting loci form a ‘poised chromatin hub’ which might recruit remodeling complexes or HATs to form a positive environment for gene expression (50, 51). As described above, it is known that chromatin remodeling proteins such as HMG proteins and the SWI/SNF complex are (in part) regulated by acetylation. Furthermore it has been shown that acetylation is deregulated in cancer cells (2, 3).

In the current study we show that VPA treatment results in dose- and time-dependent changes in the nuclear structure of PCa cell lines, reflecting change in chromatin remodeling dynamics in PCa cells. Further, these nuclear morphometric alterations can be used as a marker to measure therapeutic response. With the automated CoolScope, results can be easily calibrated and laboratory-dependent variation minimized. Of note, VPA treatment also induces nuclear structural changes in the mouse normal liver and kidney cells where it is metabolized and its breakdown products are excreted (52). These nuclear structural changes in normal liver and kidney cells may reflect underlying cause for reported elevation of liver enzyme, hepatitis, renal tubular dysfunction in children (53) and Fanconi syndrome (54, 55) during VPA treatment.

Previously, our group has shown that VPA treatment of Pca cells increases histone H3 acetylation, CK18, p21 and p27 expression, and decrease androgen receptor, cyclin D1, Ki67 expression in vitro and in vivo (56, 57). Further, chronic low dose administration of VPA results in an increase in apoptosis (assessed by TUNEL assay) and a decrease in angiogenesis (assessed by CD34 MVD) in PCa xenografts (56). The next step in our investigation, the analysis of pre-and post-treatment human PCa tissue, is not feasible for now as VPA treatment for solid tumors is only given in a clinical trial setting at the moment. Patients eligible for a clinical trial are in an end stage of their disease and typically have had a prostatectomy or chemotherapy prior to enrollment.

Supplementary tables 1 & 2 illustrate that in vitro and in vivo PCa treated cells had different structural alterations profiles. There are several potential reasons that may explain these differences. Chromatin remodelling and actin filament organisation are interacting processes (58). It is known that the nucleus forms part of a continuous physical network spanning the extracellular matrix, the cytoskeleton and the nuclear envelope. Environmentally mediated forces can be transmitted to the nucleus and induce deformations of the chromatin (59). In our experiments, in vitro cells were grown in a single layer in a dish prior to harvesting using trypsin, while in vivo cells were grown in 3D in mouse stroma and were paraffin-embedded as such. In addition, in vitro and in vivo cells have access to a different set of growth factors and other nutrients. Their microenvironment differs grossly, which might affect their type of response to VPA treatment.

The quantitative assessment of nuclear structure by digital image analysis has identified numerous potential clinical applications. Our group has previously shown that there are significant alterations in nuclear structure between and within Gleason grading patterns 3, 4, and 5 (60). Further, we demonstrated that nuclear structure analysis is of additive value with clinicopathologic parameters in the prediction of biochemical recurrence, distant metastasis, and death after radical prostatectomy (23, 24). Recently, Makarov et al. (61) used quantitative nuclear structure alterations to predict conversion to unfavorable biopsy pathology during watchful waiting surveillance. In this paper we discuss the use of nuclear structure analysis in therapeutic response measurements. Identification of proteins that modify nuclear chromatin organization is of paramount importance to improve our understanding of the biology behind these measurements. One of such proteins was HAT protein p300 has shown to predict PCa biochemical recurrence in men with long-term follow-up and correlate with changes in epithelia nuclear size and shape (62-64). The use of quantitative nuclear structure alterations and the molecular mechanisms which cause such changes provide the foundation for continued research in this area that can eventually change the management of PCa patients.

In conclusion, HDACI VPA significantly changes the epithelial nuclear structure in a time-and dose-dependent fashion in PCa both in vitro and in vivo. VPA also affects nuclear structure in normal mouse liver and kidney tissue which likely reflects a natural physiological response.

Supplementary Material

supplementary tabe 2

supplementary table 1

Acknowledgements

Shabana Shabbeer for providing xenograft material

Funding for this project was provided by The Patana Fund, The Prostate Cancer Foundation, The Johns Hopkins University Prostate Cancer SPORE (Grant number: P50CA58236), the Early Detection Research Network (EDRN) NCI/NIH (Grant number CA086323-06), Internationalization grant UMCU and the Aegon Foundation.

Abbreviations

FFPE
Formalin-Fixed Paraffin Embedded
HDACI
Histone Deacetylase Inhibitor
NMD
Nuclear Morphometric Descriptor
QNG
Quantitative Nuclear Grade
ROC
Receiver Operator Characteristic
TMA
Tissue Microarray
VPA
Valproic Acid

References

1. Kortenhorst MS, Carducci MA, Shabbeer S. Acetylation and histone deacetylase inhibitors in cancer. Cell Oncol. 2006;28:191–222. [PubMed]
2. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov. 2002;1:287–99. [PubMed]
3. Weichert W, Roske A, Gekeler V, et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol. 2008;9:139–48. [PubMed]
4. Reid T, Valone F, Lipera W, et al. Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer. 2004;45:381–6. [PubMed]
5. Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol. 2005;23:3923–31. [PMC free article] [PubMed]
6. Atmaca A, Al-Batran SE, Maurer A, et al. Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer. 2007;97:177–82. [PMC free article] [PubMed]
7. Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2007;110:2302–8. [PubMed]
8. Kim B, Ahn K, Kim I, Park I, Kim B, Yoon S. Effect of combined treatment of bortezomib and valproic acid on multiple myeloma cells.. ASCO annual meeting Proceedings Part I; 2007. p. 18539. 2007.
9. Braiteh F, Soriano AO, Garcia-Manero G, et al. Phase I Study of Epigenetic Modulation with 5-Azacytidine and Valproic Acid in Patients with Advanced Cancers. Clin Cancer Res. 2008;14:6296–301. [PMC free article] [PubMed]
10. Munster P, Marchion D, Bicaku E, et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol. 2007;25:1979–85. [PubMed]
11. Waterborg JH. Dynamics of histone acetylation in vivo. A function for acetylation turnover? Biochem Cell Biol. 2002;80:363–78. [PubMed]
12. Escargueil AE, Soares DG, Salvador M, Larsen AK, Henriques JA. What histone code for DNA repair? Mutat Res. 2008;658:259–70. [PubMed]
13. Polevoda B, Sherman F. The diversity of acetylated proteins. Genome Biol. 2002;3:reviews0006. [PMC free article] [PubMed]
14. Ferguson M, Henry PA, Currie RA. Histone deacetylase inhibition is associated with transcriptional repression of the Hmga2 gene. Nucleic Acids Res. 2003;31:3123–33. [PMC free article] [PubMed]
15. Zhang Q, Wang Y. High mobility group proteins and their post-translational modifications. Biochim Biophys Acta. 2008 [PMC free article] [PubMed]
16. Lim JH, West KL, Rubinstein Y, Bergel M, Postnikov YV, Bustin M. Chromosomal protein HMGN1 enhances the acetylation of lysine 14 in histone H3. Embo J. 2005;24:3038–48. [PMC free article] [PubMed]
17. Belova GI, Postnikov YV, Furusawa T, Birger Y, Bustin M. Chromosomal protein HMGN1 enhances the heat shock-induced remodeling of Hsp70 chromatin. J Biol Chem. 2008;283:8080–8. [PMC free article] [PubMed]
18. Townson SM, Kang K, Lee AV, Oesterreich S. Structure-function analysis of the estrogen receptor alpha corepressor scaffold attachment factor-B1: identification of a potent transcriptional repression domain. J Biol Chem. 2004;279:26074–81. [PubMed]
19. MacRae TH. Tubulin post-translational modifications--enzymes and their mechanisms of action. Eur J Biochem. 1997;244:265–78. [PubMed]
20. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci U S A. 2003;100:4389–94. [PMC free article] [PubMed]
21. Yamamichi N, Yamamichi-Nishina M, Mizutani T, et al. The Brm gene suppressed at the post-transcriptional level in various human cell lines is inducible by transient HDAC inhibitor treatment, which exhibits antioncogenic potential. Oncogene. 2005;24:5471–81. [PubMed]
22. Diamond DA, Berry SJ, Jewett HJ, Eggleston JC, Coffey DS. A new method to assess metastatic potential of human prostate cancer: relative nuclear roundness. The Journal of urology. 1982;128:729–34. [PubMed]
23. Veltri RW, Miller MC, Isharwal S, Marlow C, Makarov DV, Partin AW. Prediction of Prostate-Specific Antigen Recurrence in Men with Long-term Follow-up Postprostatectomy Using Quantitative Nuclear Morphometry. Cancer Epidemiol Biomarkers Prev. 2008;17:102–10. [PubMed]
24. Veltri RW, Khan MA, Miller MC, et al. Ability to predict metastasis based on pathology findings and alterations in nuclear structure of normal-appearing and cancer peripheral zone epithelium in the prostate. Clin Cancer Res. 2004;10:3465–73. [PubMed]
25. Partin AW, Walsh AC, Pitcock RV, Mohler JL, Epstein JI, Coffey DS. A comparison of nuclear morphometry and Gleason grade as a predictor of prognosis in stage A2 prostate cancer: a critical analysis. The Journal of urology. 1989;142:1254–8. [PubMed]
26. Epstein JI, Berry SJ, Eggleston JC. Nuclear roundness factor. A predictor of progression in untreated Stage A2 prostate cancer. Cancer. 1984;54:1666–71. [PubMed]
27. Huisman A, Ploeger LS, Dullens HF, et al. Discrimination between benign and malignant prostate tissue using chromatin texture analysis in 3-D by confocal laser scanning microscopy. Prostate. 2007;67:248–54. [PubMed]
28. Jorgensen T, Yogesan K, Tveter KJ, Skjorten F, Danielsen HE. Nuclear texture analysis: a new prognostic tool in metastatic prostate cancer. Cytometry. 1996;24:277–83. [PubMed]
29. Stein GS, Lian JB, Stein JL, et al. Combinatorial organization of the transcriptional regulatory machinery in biological control and cancer. Advances in enzyme regulation. 2005;45:136–54. [PubMed]
30. Carmichael MJ, Veltri RW, Partin AW, Miller MC, Walsh PC, Epstein JI. Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease. The Journal of urology. 1995;153:1015–9. [PubMed]
31. Gill JE, Jotz MM. Further observations on the chemistry of pararosaniline-Feulgen staining. Histochemistry. 1976;46:147–60. [PubMed]
32. Schulte E, Wittekind D. Standardization of the Feulgen-Schiff technique. Staining characteristics of pure fuchsin dyes; a cytophotometric investigation. Histochemistry. 1989;91:321–31. [PubMed]
33. Grignani F, De Matteis S, Nervi C, et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature. 1998;391:815–8. [PubMed]
34. Waltregny D, North B, Van Mellaert F, de Leval J, Verdin E, Castronovo V. Screening of histone deacetylases (HDAC) expression in human prostate cancer reveals distinct class I HDAC profiles between epithelial and stromal cells. Eur J Histochem. 2004;48:273–90. [PubMed]
35. Kachhap SK, Kortenhorst MSQ, Shabbeer S, Washington E, Carducci MA. Comparison of expression of Class I and Class II histone deacetylase in prostate cancer cell lines and normal immortalized prostate epithelial cells.. Proceedings of AACR Annual Meeting.2004.
36. Kortenhorst MS, Zahurak M, Shabbeer S, et al. A multiple-loop, double-cube microarray design applied to prostate cancer cell lines with variable sensitivity to histone deacetylase inhibitors. Clin Cancer Res. 2008;14:6886–94. [PMC free article] [PubMed]
37. Lanctot C, Cheutin T, Cremer M, Cavalli G, Cremer T. Dynamic genome architecture in the nuclear space: regulation of gene expression in three dimensions. Nat Rev Genet. 2007;8:104–15. [PubMed]
38. Gasser SM. Visualizing chromatin dynamics in interphase nuclei. Science. 2002;296:1412–6. [PubMed]
39. Cremer T, Cremer M, Dietzel S, Muller S, Solovei I, Fakan S. Chromosome territories--a functional nuclear landscape. Curr Opin Cell Biol. 2006;18:307–16. [PubMed]
40. Chubb JR, Boyle S, Perry P, Bickmore WA. Chromatin motion is constrained by association with nuclear compartments in human cells. Curr Biol. 2002;12:439–45. [PubMed]
41. Thomson I, Gilchrist S, Bickmore WA, Chubb JR. The radial positioning of chromatin is not inherited through mitosis but is established de novo in early G1. Curr Biol. 2004;14:166–72. [PubMed]
42. Heun P, Laroche T, Shimada K, Furrer P, Gasser SM. Chromosome dynamics in the yeast interphase nucleus. Science. 2001;294:2181–6. [PubMed]
43. Levi V, Ruan Q, Plutz M, Belmont AS, Gratton E. Chromatin dynamics in interphase cells revealed by tracking in a two-photon excitation microscope. Biophys J. 2005;89:4275–85. [PMC free article] [PubMed]
44. Chuang CH, Carpenter AE, Fuchsova B, Johnson T, de Lanerolle P, Belmont AS. Long-range directional movement of an interphase chromosome site. Curr Biol. 2006;16:825–31. [PubMed]
45. Kosak ST, Skok JA, Medina KL, et al. Subnuclear compartmentalization of immunoglobulin loci during lymphocyte development. Science. 2002;296:158–62. [PubMed]
46. Hewitt SL, High FA, Reiner SL, Fisher AG, Merkenschlager M. Nuclear repositioning marks the selective exclusion of lineage-inappropriate transcription factor loci during T helper cell differentiation. Eur J Immunol. 2004;34:3604–13. [PubMed]
47. Williams RR, Azuara V, Perry P, et al. Neural induction promotes large-scale chromatin reorganisation of the Mash1 locus. J Cell Sci. 2006;119:132–40. [PubMed]
48. Zink D, Amaral MD, Englmann A, et al. Transcription-dependent spatial arrangements of CFTR and adjacent genes in human cell nuclei. J Cell Biol. 2004;166:815–25. [PMC free article] [PubMed]
49. Ragoczy T, Bender MA, Telling A, Byron R, Groudine M. The locus control region is required for association of the murine beta-globin locus with engaged transcription factories during erythroid maturation. Genes Dev. 2006;20:1447–57. [PMC free article] [PubMed]
50. Spilianakis CG, Lalioti MD, Town T, Lee GR, Flavell RA. Interchromosomal associations between alternatively expressed loci. Nature. 2005;435:637–45. [PubMed]
51. Simonis M, Klous P, Splinter E, et al. Nuclear organization of active and inactive chromatin domains uncovered by chromosome conformation capture-on-chip (4C). Nat Genet. 2006;38:1348–54. [PubMed]
52. Gilman AG, Rall TW, Nies AS, Taylor P. Goodman and Gilman's the pharmacological basis of therapeutics. 8th ed. Pergamon Press; New York: 1990. Goodman and Gilman's the pharmacological basis of therapeutics. pp. 450–3.
53. Altunbasak S, Yildizas D, Anarat A, Burgut HR. Renal tubular dysfunction in epileptic children on valproic acid therapy. Pediatr Nephrol. 2001;16:256–9. [PubMed]
54. Watanabe T, Yoshikawa H, Yamazaki S, Abe Y, Abe T. Secondary renal Fanconi syndrome caused by valproate therapy. Pediatr Nephrol. 2005;20:814–7. [PubMed]
55. Knorr M, Schaper J, Harjes M, Mayatepek E, Rosenbaum T. Fanconi syndrome caused by antiepileptic therapy with valproic Acid. Epilepsia. 2004;45:868–71. [PubMed]
56. Shabbeer S, Kortenhorst MS, Kachhap S, Galloway N, Rodriguez R, Carducci MA. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo. Prostate. 2007;67:1099–110. [PubMed]
57. Xia Q, Sung J, Chowdhury W, et al. Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res. 2006;66:7237–44. [PubMed]
58. Farrants AK. Chromatin remodelling and actin organisation. FEBS Lett. 2008 [PubMed]
59. Verstraeten VL, Lammerding J. Experimental techniques for study of chromatin mechanics in intact nuclei and living cells. Chromosome Res. 2008;16:499–510. [PubMed]
60. Veltri RW, Marlow C, Khan MA, Miller MC, Epstein JI, Partin AW. Significant variations in nuclear structure occur between and within Gleason grading patterns 3, 4, and 5 determined by digital image analysis. The Prostate. 2007;67:1202–10. [PubMed]
61. Makarov DV, Marlow C, Epstein JI, et al. Using nuclear morphometry to predict the need for treatment among men with low grade, low stage prostate cancer enrolled in a program of expectant management with curative intent. The Prostate. 2008;68:183–9. [PMC free article] [PubMed]
62. Isharwal S, Miller MC, Marlow C, Makarov DV, Partin AW, Veltri RW. p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape. Prostate. 2008;68:1097–104. [PMC free article] [PubMed]
63. Debes JD, Sebo TJ, Heemers HV, et al. p300 modulates nuclear morphology in prostate cancer. Cancer Res. 2005;65:708–12. [PubMed]
64. Debes JD, Sebo TJ, Lohse CM, Murphy LM, Haugen DA, Tindall DJ. p300 in prostate cancer proliferation and progression. Cancer Res. 2003;63:7638–40. [PubMed]

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Compound
    Compound
    PubChem Compound links
  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...